Results 81 to 90 of about 125 (92)

Netakimab in treatment of moderate to severe forms of psoriasis

Medical alphabet, 2022
The article presents an overview of published sources on etiology, pathogenesis and treatment of psoriasis, and described the treatment of moderate to severe psoriasis with new biologics netakimab.
L. R. Kulikova, D. Y. Kovalenko
openaire   +1 more source

Inverse psoriasis and psoriasis of ‘difficult’ localizations: Effectiveness of netakimab

Medical alphabet, 2022
Introduction. The drug netakimab belongs to the group of IL-17A blockers and has shown high efficacy against all clinical symptoms of psoriasis vulgaris according to clinical trials and real clinical practice. At the same time, data on the effectiveness of netakimab in inverse psoriasis, psoriasis of ‘difficult’ localizations are of a single nature ...
L. S. Kruglova, N. S. Rudneva, A. L. Bakulev, A. A. Khotko   +3 more
openaire   +1 more source

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: a retrospective cohort study

2022
Background The aim of the study was to assess inflammatory markers and clinical outcomes in adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with targeted immunosuppressive therapy using anti-IL-17A (netakimab), anti-IL-6R (tocilizumab), or JAK1/JAK2 inhibitor (baricitinib) or with ...
E.A. Bryushkova, V.D. Skatova, Z.Y. Mutovina, A.I. Zagrebneva, D.S. Fomina, T.S. Kruglova, A. Akopyan, I.D. Strazhesko, S. Lukyanov, O.N. Tkacheva, M.A. Lysenko, D.M. Chudakov   +11 more
openaire   +1 more source

Anogenital psoriasis. Experience of netakimab therapy

Medical alphabet
Introduction. Diagnosis of anogenital psoriasis is complicated by the lack of awareness of doctors and the shyness of patients. The total lesion area and the severity of anogenital psoriasis are often in inverse proportion, which requires the use of systemic therapy. Aim.
M. I. Kurdina, N. G. Kolenko
openaire   +1 more source

Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults.

Clinical and experimental rheumatology, 2020
Netakimab (NTK) is a humanised monoclonal antibody targeting interleukin-17A, previously investigated in a phase 1 trial in healthy volunteers. Here, we report the results of a phase 2 trial, conducted to assess safety and pharmacokinetics (PK), to establish a therapeutic dose of NTK in a target population of patients with active ankylosing spondylitis
Shandor, Erdes, Evgeny, Nasonov, Elena, Kunder, Andrey, Pristrom, Nikolay, Soroka, Pavel, Shesternya, Tatiana, Dubinina, Svetlana, Smakotina, Tatiana, Raskina, Diana, Krechikova, Tatiana, Povarova, Tatiana, Plaksina, Ivan, Gordeev, Vadim, Mazurov, Olga, Reshetko, Elena, Zonova, Anna, Eremeeva, Ekaterina, Chernyaeva, Tatiana, Makulova, Roman, Ivanov   +19 more
openaire   +1 more source

Experience with the use of netakimab for the treatment of psoriasis in HIV-infected patients

Pharmateca, 2022
B.M. Gruzdev Gruzdev, E.V. Svechnikova Svechnikova, Zh.B. Ponezheva Ponezheva, E.Yu. Evdokimov Evdokimov   +3 more
openaire   +1 more source

Efficacy of netakimab in patients with psoriasis and disease duration up to 1 year: implementation of a strategy for early prescription of genetic engineering biological therapy

Medical alphabet
Currently, in actual clinical practice, there is an increasing consensus that early administration of a biologically active drug not only prevents the progression of the pathological process in the skin, but also prevents the development of psoriatic arthritis, and also has a beneficial effect on comorbid pathologies and complications associated with ...
L. S. Kruglova, N. O. Pereverzina, N. S. Rudneva   +2 more
openaire   +1 more source

Netakimab monotherapy for palmoplantar psoriasis

Pharmateca
Kolenko N.G. Kolenko, Kurdina M.I. Kurdina   +1 more
openaire   +1 more source

Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study

Cytokine, 2021
Natalia Trushenko, Sergey Avdeev
exaly  

Fab Fragment of VHH-Based Antibody Netakimab: Crystal Structure and Modeling Interaction with Cytokine IL-17A

Crystals, 2019
Maria Garber, Olga Kostareva, Azat Gabdulkhakov   +2 more
exaly